Publication details
Nové možnosti léčby endometriálního karcinomu
| Title in English | New treatment options for endometrial cancer |
|---|---|
| Authors | |
| Year of publication | 2023 |
| Type | Article in Periodical |
| Magazine / Source | Farmakoterapie |
| MU Faculty or unit | |
| Citation | |
| web | https://www.farmakoterapie.cz/c7440/nove-moznosti-lecby-endometrialniho-karcinomu |
| Keywords | endometrial carcinoma; treatment |
| Description | This review summarizes the results of clinical trials conducted in patients with advanced endometrial cancer. The new drugs in endometrial cancer are related to conventional chemotherapy and belong to the armamentarium of treatment of advanced, metastatic and recurrent stages of the disease, which still have a poor prognosis. Early stages are usually managed by surgery (possibly in combination with adjuvant radiotherapy and/or platinum-based chemotherapy). Endometrial carcinoma is a good candidate for immuno-oncotherapy because of the frequent presence of hypermutated cell subtypes (so-called dMMR/MSI-H subtypes). New developments in systemic treatment of advanced and recurrent stages include monoclonal antibodies (lenvatinib, trastuzumab), checkpoint inhibitors (dostarlimab, pembrolizumab) and targeted drugs (especially from the kinase inhibitor group). In clinical practice, the efficacy of immuno-oncotherapeutics in monotherapy has been confirmed to be low in gynaecological malignancies; they are usually combined with conventional chemotherapy or targeted drugs. An exception is hypermutated dMMR/MSI-H endometrial cancer, in the treatment of which significant results have been described with the administration of deliverlimab in monotherapy. In combination therapy, the best results were achieved with the administration of the anti-angiogenic drug lenvatinib and the checkpoint inhibitor pembrolizumab, independent of the mutational status of the cancer cells. The significance of the success of these therapeutics is demonstrated by a recent change in the recommended guidelines of the Czech Oncological Society. |